Coronary Artery Disease  >>  inclacumab (PF-07940370)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
inclacumab (PF-07940370) / Roche, Pfizer, Genmab
NCT01327183 / 2011-001365-40: A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Checkmark SELECT- ACS
Mar 2013 - Mar 2013: SELECT- ACS
Checkmark ACC 2013: SELECT-ACS: During PCI in patients with NSTEMI
Mar 2013 - Mar 2013: ACC 2013: SELECT-ACS: During PCI in patients with NSTEMI
Checkmark Myocardial damage
More
Completed
2
532
US, Canada, Europe
Percutaneous Coronary Intervention (PCI), RO4905417, placebo
Hoffmann-La Roche
Myocardial Infarction
10/12
10/12
NCT01245634: A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

Completed
2
384
US, Canada
Placebo, RO4905417
Hoffmann-La Roche
Coronary Heart Disease, Graft Occlusion, Vascular
05/13
05/13

Download Options